NCT07192471 2025-09-25
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Kyowa Kirin Co., Ltd.
Phase 1 Not yet recruiting
Kyowa Kirin Co., Ltd.
miRagen Therapeutics, Inc.
miRagen Therapeutics, Inc.